- In pregnant with gestational hypertension (GH), home blood pressure monitoring (HBPM) was significantly associated with reduction in antenatal visits compared with office (traditional) BP measurement.
- Adverse maternal and perinatal outcomes were comparable between both groups.
Why this matters
- Findings expand the maternal, foetal and neonatal safety data of the use of HBPM during pregnancy.
- Large trials are needed to ascertain the safety of rare adverse pregnancy outcomes.
- Cohort study of 143 pregnant women with GH, who followed an individualised schedule of hospital visits and BP measurements based on the HBPM (n=80) or standard care (control group; n=63) as per the National Institute of Health and Care Excellence guideline (NICE) guideline.
- Main outcomes: difference in adverse foetal, neonatal and maternal outcomes, and number of antenatal hospital visits between HBPM and standard care.
- Funding: The Health Foundation.
- No significant difference observed between HBPM and control groups in:
- maternal high-dependency unit admission (P=.999),
- birth weight centile (P=.803),
- foetal growth restriction (P=.999),
- neonatal intensive care unit admissions (P=.507),
- composite neonatal (P=.654), maternal or foetal adverse outcomes (P=.999 for both) and
- total number of outpatient (P=.357) and triage visits (P=.237).
- After adjustment for the duration of monitoring per weeks:
- The number of day assessment unit visits was significantly lower in the HBPM vs control group (median, 1.0 vs 1.5; P<.001>
- HBPM vs control group had a significant reduction in the number of total antenatal visits (median, 1.4 vs 1.8; P=.020).
- Risk of bias.
- Small sample size.